Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Lucyna Cova"'
Autor:
Bénédicte Ndeboko, Narayan Ramamurthy, Guy Joseph Lemamy, Catherine Jamard, Peter E. Nielsen, Lucyna Cova
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 9, Iss C, Pp 162-169 (2017)
Peptide nucleic acids (PNAs) are potentially attractive antisense agents against hepatitis B virus (HBV), although poor cellular uptake limits their therapeutic application. In the duck HBV (DHBV) model, we evaluated different cell-penetrating peptid
Externí odkaz:
https://doaj.org/article/36eeb876da62402ea54601da576d55b9
Autor:
Ingo Roehl, Stephan Seiffert, Celia Brikh, Jonathan Quinet, Catherine Jamard, Nadine Dorfler, Jennifer A. Lockridge, Lucyna Cova, Andrew Vaillant
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 8, Iss , Pp 1-12 (2017)
REP 2139 is a nucleic acid polymer (NAP) currently under clinical development for chronic hepatitis B (HBV) therapy. This preclinical study investigated different REP 2139 analogs that would display reduced accumulation in the serum and tissues, whil
Externí odkaz:
https://doaj.org/article/93acc5b5558548d5b44948a5ea011ad2
Publikováno v:
Biomolecules, Vol 8, Iss 3, p 55 (2018)
Alternative therapeutic approaches against chronic hepatitis B virus (HBV) infection need to be urgently developed because current therapies are only virostatic. In this context, cell penetration peptides (CPPs) and their Peptide Nucleic Acids (PNAs)
Externí odkaz:
https://doaj.org/article/81a3f3676f724e69832557ff81fd8555
Potent inhibition of late stages of hepadnavirus replication by a modified cell penetrating peptide.
Autor:
Fabien Abdul, Bénédicte Ndeboko, Thierry Buronfosse, Fabien Zoulim, Michael Kann, Peter E Nielsen, Lucyna Cova
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e48721 (2012)
Cationic cell-penetrating peptides (CPPs) and their lipid domain-conjugates (CatLip) are agents for the delivery of (uncharged) biologically active molecules into the cell. Using infection and transfection assays we surprisingly discovered that CatLi
Externí odkaz:
https://doaj.org/article/a6db9dfa97ac4aaaa5b90aaa2a3b0786
Publikováno v:
Hépatite B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2aa1846aa283035a9097f262523d80
https://doi.org/10.1051/978-2-84254-223-8.c032
https://doi.org/10.1051/978-2-84254-223-8.c032
Autor:
Sylviane Guerret, Jonathan Quinet, Madeleine Burtin, Catherine Jamard, Camille Sureau, Lucyna Cova, Matthieu Lemasson, Andrew Vaillant
Publikováno v:
Hepatology
Hepatology, Wiley-Blackwell, 2018, 67 (6), pp.2127-2140. ⟨10.1002/hep.29737⟩
Hepatology, Wiley-Blackwell, 2018, 67 (6), pp.2127-2140. ⟨10.1002/hep.29737⟩
Nucleic acid polymer (NAP) REP 2139 treatment was shown to block the release of viral surface antigen in duck HBV (DHBV)-infected ducks and in patients with chronic HBV or HBV/hepatitis D virus infection. In this preclinical study, a combination ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09985c04ebc2793dcc4b65796003046c
https://hal.archives-ouvertes.fr/hal-02370863
https://hal.archives-ouvertes.fr/hal-02370863
Autor:
Narayan Ramamurthy, Guy Joseph Lemamy, Lucyna Cova, Peter E. Nielsen, Bénédicte Ndeboko, Catherine Jamard
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 9, Iss C, Pp 162-169 (2017)
Ndeboko, B, Ramamurthy, N, Lemamy, G J, Jamard, C, Nielsen, P E & Cova, L 2017, ' Role of Cell-Penetrating Peptides in Intracellular Delivery of Peptide Nucleic Acids Targeting Hepadnaviral Replication ', Molecular Therapy-Nucleic Acids, vol. 9, pp. 162-169 . https://doi.org/10.1016/j.omtn.2017.09.003
Molecular Therapy: Nucleic Acids, Vol 9, Iss C, Pp 162-169 (2017)
Ndeboko, B, Ramamurthy, N, Lemamy, G J, Jamard, C, Nielsen, P E & Cova, L 2017, ' Role of Cell-Penetrating Peptides in Intracellular Delivery of Peptide Nucleic Acids Targeting Hepadnaviral Replication ', Molecular Therapy-Nucleic Acids, vol. 9, pp. 162-169 . https://doi.org/10.1016/j.omtn.2017.09.003
Peptide nucleic acids (PNAs) are potentially attractive antisense agents against hepatitis B virus (HBV), although poor cellular uptake limits their therapeutic application. In the duck HBV (DHBV) model, we evaluated different cell-penetrating peptid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74a5c01a87d5384b48d8dc066564904a
https://pubmed.ncbi.nlm.nih.gov/29246295
https://pubmed.ncbi.nlm.nih.gov/29246295
Autor:
Lucyna Cova
Publikováno v:
Current Gene Therapy. 14:149-160
Despite the existence of an effective prophylactic vaccine, chronic hepatitis B virus (HBV) infection remains a major public health problem. Because very weak and functionally impaired virus-specific immune responses play a key role in the persistenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf4754965da4cc573e00818dab83d9af
https://doi.org/10.2174/1566523214666140509102644
https://doi.org/10.2174/1566523214666140509102644
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:1154-1157
Examples of ring-expanded nucleosides (RENs), represented by general structures 1 and 2, exhibited dual anti-HCV and anti-HIV activities in both cell culture systems and the respective target enzyme assays, including HCV NTPase/helicase and human RNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7f7787cad9a5ae19e9b9a6674b519ab
https://doi.org/10.1016/j.bmcl.2013.12.121
https://doi.org/10.1016/j.bmcl.2013.12.121
Autor:
Lucyna Cova
Publikováno v:
Expert opinion on biological therapy. 17(2)
With at least 240 million hepatitis B virus (HBV) carriers worldwide, being at a high risk of cirrhosis and hepatocellular carcinoma (HCC), chronic hepatitis B remains a major public health issue. Because current antiviral treatments are only virosta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9108cc0a3e82767b4dc863466c1bac2
https://pubmed.ncbi.nlm.nih.gov/27892722
https://pubmed.ncbi.nlm.nih.gov/27892722